Business
Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones
Fourth quarter revenue up 16% year-over-year, $26.9M of secured debt eliminated, and total cash and escrowed proceeds of $44.3M at year-end GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a corporate update and outlined upcoming development milestones for NXT-41x, its next-generation antibiotic-eluting biomatrix program in plastic and reconstructive surgery. NXT-41x is El
About this update from Elutia, Inc.
[{"type":"image","alt":"Elutia Inc.","displaySize":"","headline":null,"caption":"Elutia Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":67,"url":"https://media.zenfs.com/en/globenewswire.com/a29e66fb8a73dd1618af733c91ecea76"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/c1mHLTLmof012jV7WnpAyg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a29e66fb8a73dd1618af733c91ecea76","width":300,"height":67}},"lazy":false},{"type":"text","content":"Fourth quarter revenue up 16% year-over-year, $26.9M of secured debt eliminated, and total cash and escrowed proceeds of $44.3M at year-end","length":139,"tagName":"p"},{"type":"text","content":"GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a corporate update and outlined upcoming development milestones for NXT-41x, its next-generation antibiotic-eluting biomatrix program in plastic and reconstructive surgery.","length":346,"tagName":"p"},{"type":"text","content":"NXT-41x is Elutia’s next-generation antibiotic-eluting biomatrix, built on the Company’s technology platform that was clinically and commercially validated with EluPro, indicated for use with pacemaker placement. EluPro was divested to Boston Scientific in October of 2025 for $88 million. The Company believes the NXT-41x platform has the potential to significantly improve outcomes in breast reconstruction, a $1.5 billion market currently with a post-operative infection rate of 15-25%.","length":489,"tagName":"p"},{"type":"text","content":"Elutia is advancing development of its NXT-41 biomatrix platform and remains on track for planned regulatory milestones. Upcoming milestones include submission of an FDA filing for NXT-41, the Company’s novel base matrix, in the first half of 2026, with anticipated FDA clearance in the second half of 2026. Building on this foundation, Elutia anticipates FDA clearance for NXT-41x, the antibiotic-eluting version of the biomatrix, in the first half of 2027.","length":458,"tagName":"p"},{"type":"text","content":"Preliminary Fourth Quarter 2025 Financial Results ","length":49,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Preliminary net sales. For the fourth quarter of 2025, preliminar...